Key figures
Nightingale Health's key figures
EUR thousand | Group | |||
2021–2022 | 2020–2021 | |||
Revenue | 2,313 | 2,305 | ||
EBITDA | -9,389 | -7,301 | ||
Operating profit (loss) | -13,634 | -9,754 | ||
Net income (loss) for the financial period | -16,091 | -9,725 | ||
Equity ratio | 91% | 90% | ||
Net debt to equity ratio | -78% | -84% | ||
Balance sheet total | 124,048 | 138,987 | ||
Number of employees on average | 64 | 76 | ||
Personnel expenses | -6,499 | -6,365 | ||
Cash and cash equivalents at the end of the period | 95,279 | 113,807 | ||
Earnings per share (EPS), undiluted and diluted*, EUR | -0.27 | -0.23 | ||
*) The company’s potential dilutive instruments consist of stock options. As the company’s business has been unprofitable, stock options would have an anti-dilutive effect and therefore they are not taken into account in calculating the dilutive loss per share. Thus, there is no difference between the undiluted and diluted earnings per share.
Calculation of key figures
Key figure |
Formula |
EBITDA |
Operating profit (loss) before depreciation and amortization |
Operating profit (loss) |
Profit (loss) before income taxes and financial income and expenses |
Equity ratio, % |
Total equity / (Balance sheet total – deferred income) |
Net debt to equity ratio, % |
Net debt /Total equity |
Earnings per share (EPS), undiluted, EUR |
Profit (loss) for the period / Weighted average number of shares outstanding during the period |
Earnings per share (EPS), diluted, EUR |
Profit (loss) for the period / Weighted average number of shares outstanding during the period + potential dilutive shares |